The injectable product is being dispensed for the treatment of type 2 diabetes. Its active ingredient, semaglutide, plays a role in controlling blood sugar, stimulating insulin secretion when blood glucose is high, slowing gastric emptying, and suppressing appetite, which leads to Significant weight loss of about 10% in one year.
An American user of the platform recounted, in a video clip watched by 100,000, her experience with the drug, adding that its effect was good for her despite its use only 6 weeks ago, as she appeared thinner before taking it.
And the company that manufactured the drug obtained a license to market it in several countries as a stronger dose and under another name, “Wegovi”, for the purpose of treating obesity.
Jean-Francois Thibault from the Diabetes Federation in France expressed her concern about the potential rush to it, especially that it is highly effective against diabetes, while Karen Clement, an obesity specialist at the National Institute of Health and Medical Research, stressed the need to organize it well, indicating that it is not magical.